The goal of cancer immunotherapy is to enable the patient’s own immune system to recognize and target cancer cells. Therefore, cancer immunotherapy is distinctly different from chemotherapy, which primarily targets rapidly dividing cells. However, the effectiveness of cancer immunotherapy, potential side effects and application in clinical settings can vary greatly from patient to patient, depending on cancer type and characteristics, as well as individual patient factors.
Healthcare professionals from relevant oncology disciplines will benefit from this article, which summarizes current cancer immunotherapies, their side effects and patient-specific factors influencing treatment outcomes.
Table of Contents
Understanding Cancer Immunotherapy and Its Mechanism
In their cancerous form, tumor cells can evade the immune system. Many tumors express proteins on their surface that interact with the immune checkpoints PD-1, PD-L1 and CTLA-4, which are involved in regulating T-cell activity. This results in T cells losing their activating signals and, consequently, their ability to fight the tumor.
Immune checkpoint inhibitors, i.e., anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies, act by blocking immune checkpoint pathways and restoring aspects of T-cell activity against tumors.
Other approaches to cancer immunotherapy include monoclonal antibodies (mAbs), adoptive cell therapies, cancer vaccines and cytokine-based therapies. Most of the strategies mentioned above are used depending on the type of cancer, the stage of the disease and the evidence from clinical studies.
Symptoms Associated with Cancer Immunotherapy
Because of differences in therapeutic effects and toxicities between different types of immunotherapies, symptoms and signs can vary from patient to patient. While some symptoms are generally related to treatment side effects, others are immune-mediated and cause inflammation in normal organs and tissues.
Common Treatment-Related Symptoms
Common symptoms reported during immunotherapy include:
- Fatigue: A general feeling of exhaustion or tiredness that lasts for a prolonged period.
- Skin reactions: These can present as a rash, itchy skin, redness or other skin-related issues.
- Gastrointestinal symptoms: Nausea, vomiting, diarrhea or abdominal pain.
- Musculoskeletal symptoms: These include joint pain and muscle aches.
- Flu-like symptoms: These include fever, chills and fatigue. They can occur as part of the body’s response to cancer treatment, particularly in patients receiving certain immunotherapies.
The severity of side effects associated with cancer treatment using immunotherapy can vary from patient to patient. Differentiation of treatment-related side effects from symptoms of cancer or other diseases must be based on clinical assessment.
Immune-Related Adverse Events
As the name suggests, the immune system can be driven to attack healthy tissues, an event that can occur at any time during or even after the cessation of therapy. These are collectively referred to as immune-related adverse events (irAEs).
Important immune-related complications include:
- Pneumonitis: Inflammation of lung tissue, which can cause symptoms such as cough, shortness of breath or decreased oxygen levels.
- Colitis: Inflammation of the colon or large intestine. Patients with this type of irAE can experience diarrhea, severe abdominal pain and changes in their bowel movements.
- Hepatitis: Liver inflammation of immune-mediated origin, which can be detected through elevated liver enzyme levels.
- Endocrine disorders: Inflammation of the thyroid gland (thyroiditis), pituitary gland (hypophysitis) or adrenal glands, potentially causing hormonal disturbances.
- Nephritis: Inflammation of the kidneys, which can decrease kidney function.
- Myocarditis: Inflammation of the heart muscle, which can have serious consequences for cardiac function.
- Neurological complications: Inflammatory diseases of the nervous system, which may present with symptoms such as weakness and sensory disturbances.
Timely recognition and proper management of irAEs are critical, as some can become serious or even life-threatening.
Treatment Approaches in Cancer Immunotherapy
Immunotherapy can be used to treat a variety of cancers at different stages, based on individual tumor molecular characteristics and previous treatments. Approaches include the use of immune checkpoint inhibitors, monoclonal antibodies and/or adoptive cell therapies, either as single agents or in combination with other systemic therapies.
Some of the most common types of immune checkpoint inhibitors are PD-1 inhibitors. These drugs work by preventing the interaction of PD-1 with its ligands, which helps restore T-cell activity against tumors.
Tislelizumab is a humanized IgG4 monoclonal antibody that targets PD-1. Clinical studies have evaluated tislelizumab in patients with esophageal squamous cell carcinoma (ESCC), gastric cancer and gastroesophageal junction adenocarcinoma.
Tislelizumab has been evaluated both as a monotherapy and in combination with chemotherapy across multiple cancer types in clinical trials. Its use is subject to relevant regulatory approvals and prescribing information. Treatment may be administered alone or in combination with other therapies, such as radiation or other systemic anticancer drugs.
Immunotherapies can be used alone or in combination with other cancer therapies, such as chemotherapy, radiation and/or other types of systemic treatment. Many of these treatment approaches are being studied in ongoing clinical trials to assess safety, efficacy and appropriate patient populations.
Patient Considerations Before Starting Immunotherapy
Prior clinical history, tumor characteristics and potential treatment-related toxicities are important considerations before starting immunotherapy.
Important considerations include:
- Cancer type and stage: The type of cancer and its stage are key to determining whether immunotherapy is an option.
- Biomarker assessment: Analysis of PD-L1 expression and other relevant biomarkers, such as tumor microsatellite instability (MSI), mismatch repair deficiency (dMMR) and tumor mutational burden (TMB), for specific indications.
- Previous treatments: Patients’ history of chemotherapy, radiotherapy, targeted therapy or immunotherapy.
- Pre-existing medical conditions: For example, autoimmune diseases, previous organ transplants and current organ impairment.
- Concurrent medications: Patients must be asked about any other systemic or local treatments they are currently receiving and any medications they have recently stopped taking. Immunotherapy can interact with these treatments and may increase the risk of adverse reactions.
Biomarker information needs to be interpreted in conjunction with clinical and pathological information and not in isolation.
Monitoring and Management During Treatment
Healthcare providers regularly assess clinical signs and symptoms of change (i.e., worsening or new symptoms), including vital signs, complete blood counts and clinical chemistry parameters, as well as liver, renal and thyroid function.
Additionally, healthcare professionals should monitor any new or worsening respiratory, gastrointestinal, cardiovascular, neurological or skin symptoms.
The management of organ damage caused by immune-related toxicity depends on the organ involved and the degree of toxicity. Mild, moderate or severe organ damage may require supportive care, temporary withdrawal of immunotherapy, corticosteroids or other immunosuppressive agents. Immunotherapy may need to be discontinued in cases of severe or life-threatening toxicity.
It is also very important to inform patients and their caregivers about symptoms that may require urgent medical assessment and how to report any new or worsening signs or symptoms.
Future Considerations in Cancer Immunotherapy
Further research is required into cancer immunotherapy to identify optimal predictive biomarkers and understand the mechanisms by which cancer cells can suppress the cancer-killing activity of the immune system. Strategies to manage toxicities that can occur because of immune system activation are also required. The optimal treatment duration and the appropriate patient groups for cancer immunotherapy in individual tumor types also require clarification.
Individualized cancer treatment based on the latest evidence, appropriate diagnostic and oncological assessments, and close monitoring for signs of recurrence or treatment-related side effects is important. Healthcare professionals must remain up to date with potential tumor-related and therapy-related symptoms and complications.
Disclaimer: This article is intended to provide a general overview of developments in oncology research and development. It is not intended to promote or recommend any specific treatment, product, or company. Information regarding investigational therapies reflects ongoing research and should not be interpreted as evidence of safety, efficacy, or regulatory approval. Readers are encouraged to consult healthcare professionals for the most current information.

